They are often reversible with dose reduction or cessation of Cordarone treatment. Most of the adverse effects appear to become more frequent with continued treatment beyond six months, although rates appear to remain relatively constant beyond one year. The time and dose relationships of adverse effects are under continued study. Asymptomatic corneal microdeposits are present in virtually all adult patients who have been on drug for more than 6 months.
Some patients develop eye symptoms of halos, photophobia , and dry eyes.
Vision is rarely affected and drug discontinuation is rarely needed. Sunscreen and protection from sun exposure may be helpful, and drug discontinuation is not usually necessary. Prolonged exposure to Cordarone occasionally results in a blue-gray pigmentation. This is slowly and occasionally incompletely reversible on discontinuation of drug but is of cosmetic importance only. Bradycardia usually responds to dosage reduction but may require a pacemaker for control.